Mirum Pharmaceuticals
MIRM
112 hedge funds and large institutions have $673M invested in Mirum Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 14 closing their positions.
3,640% more call options, than puts
Call options by funds: $374K | Put options by funds: $10K
71% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 28
25% more capital invested
Capital invested by funds: $540M → $673M (+$133M)
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
3% more funds holding
Funds holding: 109 → 112 (+3)
1.07% more ownership
Funds ownership: 92.11% → 93.18% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$30.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$15.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.9M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$8.59M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$29.2M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.26M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$4.6M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$3.07M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.86M |
MIRM Hedge Fund Activity: Q3 2022 in Review
112 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2022, worth a combined $673M — up 25% from $540M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MIRM positions and 14 closed out — a net gain of 3 holders — while 48 added to existing stakes and 28 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $30.7M. The largest seller was Deerfield Management, cutting an estimated $29.2M.
- 112 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2022, up from 109 in Q2 2022.
- Funds reported $673M of Mirum Pharmaceuticals stock for Q3 2022, up 25% quarter-over-quarter.
- 17 funds opened new Mirum Pharmaceuticals positions in Q3 2022 and 14 closed out, a net change of +3 holders.
- The largest Mirum Pharmaceuticals buyer in Q3 2022 was Eventide Asset Management, an estimated $30.7M added.
- The largest Mirum Pharmaceuticals seller in Q3 2022 was Deerfield Management, an estimated $29.2M sold.
Based on aggregated 13F filings for Q3 2022.